Merck: Keytruda clinical trial reaches target

(CercleFinance.com) - On Thursday Merck reported positive results from a clinical trial of its lead anti-cancer drug Keytruda in kidney cancer.


The US biopharmaceutical company said a Phase III study of its blockbuster immunotherapy met its primary endpoint of improving patient survival without disease recurrence.

The trial will now continue to measure overall patient survival, the study's secondary endpoint.

Keytruda was approved in the US two years ago for the treatment of advanced renal cell carcinoma.

The results published today show that the drug is equally effective in early forms of the disease, after surgery, the company said.


Copyright (c) 2021 CercleFinance.com. All rights reserved.